Authors


Sravanti Rangaraju, MD

Latest:

Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows

Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.


David Ziegler, MD, PhD

Latest:

Dr Ziegler on Tovorafenib in Pediatric Low-Grade Glioma

David Ziegler, MD, PhD, discusses findings from the phase 2 FIREFLY-1 trial of tovorafenib in pediatric patients with low-grade glioma.


Wade Thomas Iams, MD

Latest:

Dr Iams on the Impact of Adagrasib on Patient Outcomes in KRAS G12C–Mutant NSCLC

Wade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.


Samuel Ahuno

Latest:

Ahuno on Bringing Precision Medicine in Cancer Care to Ghana

Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.


Ashish Manne, MBBS

Latest:

Dr. Manne on the Need for Novel Therapies in HCC Without Preserved Liver Function

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.


Raymond Mailhot Vega, MD, MPH

Latest:

Dr Vega on an Analysis of Outcomes with Axillary Surgery in Breast Cancer Post-Neoadjuvant Chemo

Raymond Mailhot Vega, MD, MPH, discusses the efficacy of axillary surgery in patients with breast cancer previously given neoadjuvant chemotherapy, according to findings from a retrospective analysis.


Cynthia Lynch, MD

Latest:

Treating Brain Metastases and the future of HER2+ mBC

Closing out her discussion on HER2+ metastatic breast cancer, Cynthia Lynch, MD, shares her excitement for treatment strategies in the setting of brain metastases.


Fredrik Schjesvold, MD, PhD

Latest:

Dr. Schjesvold on OCEAN Trial Takeaways With Melflufen in Relapsed/Refractory Myeloma

Fredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.


Timothy M. Pawlik, MD, PhD, MPH

Latest:

Dr. Pawlik on Advances in Management of mCRC With Liver Metastases

Timothy M. Pawlik, MD, PhD, MPH, discusses advances in the management of patients with metastatic colorectal cancer with liver metastases.


Marc S. Hoffman, MD

Latest:

Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.


Gloria Marquina, MD, PhD

Latest:

Dr Marquina on the Importance of Referring Patients With GIST to Specialized Sarcoma Centers

Gloria Marquina, MD, PhD, as well as the need to consider ongoing clinical trials for patients with gastrointestinal stromal tumors vs treatment with the current second-line standard-of-care agent sunitinib.


Pere Barba, MD, PhD

Latest:

Dr. Barba on the Safety of Obecabtagene Autoleucel in Relapsed/Refractory B-ALL

Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.


Diana Sutherland, NP

Latest:

Sutherland on the Promise of CDK4 Inhibitors in Metastatic Breast Cancer

Diana Sutherland, NP, discusses the promise of CDK4 inhibitors in patients with metastatic breast cancer.


Akriti Jain, MD

Latest:

Dr Jain on the VERONA Study in Higher-Risk MDS

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.


Kandra Horne, DNP, MSN, WHNP-BC

Latest:

Breast Cancer Treatment: Sequencing With Antibody-Drug Conjugates

Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.


Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute

Latest:

Perspectives on Treating CCA Moving Forward

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.



Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine

Latest:

California Doctor Receives Northwestern Medicine’s First Combined Lung-Liver Transplant for Advanced Lung Cancer

Gary Gibbon, MD, pulmonologist and allergist, visited Chicago for a first-of-its-kind transplant procedure, becoming the first person in the U.S. to receive a double-lung and liver transplant for advanced lung cancer.


Ivan Marazzi, PhD

Latest:

Dr. Marazzi on the Goals of Examining Topotecan in COVID-19 and Cancer

Ivan Marazzi, PhD, discusses the goals for examining topotecan as a treatment for patients with COVID-19 and cancer in India and Brazil.


Ithaar Derweesh, MD

Latest:

Frontline Therapeutic Planning for Metastatic Renal Cell Carcinoma

In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.


Bruno B. Bockorny, MD

Latest:

Dr Bockorny on Botensilimab Plus Balstilimab in Ovarian Cancer

Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.


Amy L. Cummings, MD

Latest:

Dr Cummings on Adjuvant Osimertinib in EGFR-Mutant NSCLC

Amy L. Cummings, MD, PhD, discusses key findings from the phase 3 ADAURA trial in patients with non–small cell lung cancer harboring EGFR mutations.


Jing-Yi Chern, MD, ScM

Latest:

Dr. Chern on Outcomes With PARP Inhibitors in Recurrent Ovarian Cancer

Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.


Mary F. Mulcahy, MD

Latest:

Dr. Mulcahy on the Design of the EPOCH Trial in mCRC With Liver Metastases

Mary F. Mulcahy, MD, discusses the design of the phase 3 EPOCH trial in patients with metastatic colorectal cancer and liver metastases.


Amir Fathi, MD

Latest:

Dr Fathi on Ziftomenib in R/R NPM1-Mutant AML

Amir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.


UAMS Winthrop P. Rockefeller Cancer Institute

Latest:

Pebbles Fagan, Ph.D., MPH, Joins Leadership Team at UAMS Winthrop P. Rockefeller Cancer Institute

Pebbles Fagan, Ph.D., MPH, has assumed the role of associate director for Cancer Prevention and Control for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences.


Marilena Tauro, PhD

Latest:

Dr Tauro on the Rationale for Investigating ULK3 in Multiple Myeloma

Marilena Tauro, PhD, discusses the investigation of ULK3 in patients with multiple myeloma.


Ehab L. Atallah, MD

Latest:

Closing Thoughts on the MDS Treatment Landscape

Following its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.



Colin Burnett, MSc

Latest:

How to Improve Care for LGBTQI+ Patients With Cancer

As more and more people in the United States identify as lesbian, gay, bisexual, transgender, queer, intersex, or other sexual orientation or gender minority, the population of LGBTQI+ cancer survivors is becoming uniquely heterogeneous.